- Conditions
- Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
- Interventions
- T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
- Diagnostic Test
- Lead sponsor
- Hikari Dx, Inc.
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–41
of 41
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease
- Interventions
- prasugrel, clopidogrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Cincinnati, Ohio
- Conditions
- Bleeding Complications
- Interventions
- Clopidogrel, Prasugrel, Tricagrelor
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Coronary Artery Disease
- Interventions
- prasugrel, clopidogrel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Baltimore, Maryland • Cincinnati, Ohio
- Conditions
- Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
- Interventions
- Placebo Oral Tablet, Prasugrel Oral Tablet
- Drug
- Lead sponsor
- Elliot Israel, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cardiovascular Disease
- Interventions
- Not listed
- Lead sponsor
- Medco Health Solutions, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4,471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Franklin Lakes, New Jersey
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel, Clopidogrel
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio
- Conditions
- Cardiovascular Diseases, Acute Coronary Syndrome
- Interventions
- clopidogrel, prasugrel
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 20 Years to 74 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Newark, Delaware • Baltimore, Maryland • Danville, Pennsylvania
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel, Ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Coronary Artery Disease, Platelet Aggregation Inhibitors, PCI- Percutaneous Coronary Intervention
- Interventions
- Loading Dose Arm, Maintenance Dose Arm
- Drug
- Lead sponsor
- St. Francis Hospital, New York
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Roslyn, New York
- Conditions
- Coronary Artery Bypass
- Interventions
- Prasugrel, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- San Francisco, California • Gainesville, Florida • Chicago, Illinois + 1 more
- Conditions
- Coronary Arterial Disease (CAD)
- Interventions
- Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Acute Coronary Syndrome
- Interventions
- Polypill
- Combination Product
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 4
- States / cities
- Dallas, Texas
- Conditions
- Acute Coronary Syndrome
- Interventions
- Clopidogrel, Prasugrel, Commercially-available Aspirin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9,326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 165
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 162 more
- Conditions
- Coronary Arteriosclerosis, Acute Coronary Syndrome
- Interventions
- prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 9
- States / cities
- Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
- Conditions
- Cardiovascular Disease
- Interventions
- ticagrelor, prasugrel, Placebo
- Drug
- Lead sponsor
- Yochai Birnbaum
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Houston, Texas